Guidance document : fees for the right to sell drugs. : H13-9/13-2019E-PDF
"Once a drug is authorized for sale in Canada, industry must pay an annual fee to retain the right to sell the drug in Canada. Health Canada has charged fees since 1995 in order to recover some of the associated costs with post-market regulatory activities such as assessing safety signals and trends and communicating about risks. This document provides guidance on how fees for the right to sell drugs will be administered in accordance with the Food and Drugs Act and as stipulated in the Fees in Respect of Drugs and Medical Devices Order and the Regulations Amending and Repealing Certain Regulations Made under the Financial Administration Act"--Introduction, page 6.
Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.866809&sl=1
| Ministère/Organisme | Canada. Health Canada, issuing body. |
|---|---|
| Titre | Guidance document : fees for the right to sell drugs. |
| Variante du titre | Fees for the right to sell drugs |
| Type de publication | Monographie |
| Langue | [Anglais] |
| Autres langues publiées | [Français] |
| Édition précédente | Guidance document |
| Format | Électronique |
| Document électronique | |
| Note(s) | Issued also in French under title: Ligne directrice : frais à payer pour le droit de vendre un médicament. "Pub.: 180725." Issued also in HTML format. |
| Information sur la publication | Ottawa, Ontario : Health Canada = Santé Canada, November 2019. ©2019 |
| Description | 1 online resource (11 pages) |
| ISBN | 9780660235646 |
| Numéro de catalogue |
|
| Descripteurs | Drug approval -- Canada. Fees, Administrative -- Canada. |
Demander des formats alternatifs
Pour demander une publication dans un format alternatif, remplissez le formulaire électronique des publications du gouvernement du Canada. Utilisez le champ du formulaire «question ou commentaire» pour spécifier la publication demandée.- Date de modification :